-
Je něco špatně v tomto záznamu ?
No differences were observed in the prevention of necrotizing enterocolitis and late-onset sepsis among preterm infants who received either single-species or multi-species probiotics
P. Korček, Z. Straňák
Jazyk angličtina Země Irsko
Typ dokumentu časopisecké články
- MeSH
- lidé MeSH
- nekrotizující enterokolitida * prevence a kontrola epidemiologie MeSH
- nemoci nedonošenců prevence a kontrola epidemiologie MeSH
- novorozenec nedonošený * MeSH
- novorozenec MeSH
- probiotika * terapeutické užití MeSH
- retrospektivní studie MeSH
- sepse prevence a kontrola epidemiologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Probiotic prophylaxis has been suggested to reduce the incidence of necrotizing enterocolitis (NEC) and late-onset sepsis (LOS) in very preterm newborns. However, choosing the optimal probiotic is difficult due to variations in strain-specific effects and interactions facilitated by the use of combination species. AIMS: To compare clinical outcomes of very preterm infants receiving multi or single-species probiotics. STUDY DESIGN: Retrospective, single-center, cohort study. SUBJECTS: Very preterm infants (<32 weeks' gestation) born between 2019 and 2022 at a tertiary perinatal center received either a multi-species (Lactobacillus rhamnosus 45 %, Lactobacillus casei 15 %, Lactobacillus acidophilus 15 %, Bifidobacterium infantis 15 %, Bifidobacterium bifidum 10 %; n = 228) or a single-species (Bifidobacterium breve BR03 and B632; n = 227) probiotic formulation. MAIN OUTCOME MEASURES: NEC, LOS, and mortality. RESULTS: The overall incidence of NEC and LOS was 3.1 % and 13.8 %, respectively. There were no differences between the multi-species and single-species probiotic groups in the rate of NEC (3.5 % vs 2.6 %; p = 0.787), LOS (15.4 % vs 12.3 %; p = 0.416), mortality (0.9 % vs 1.8 %; p = 0.449), or composite outcome (NEC, LOS and/or death; 16.7 % vs 12.8 %; p = 0.290). CONCLUSION: The clinical outcomes of very preterm newborns receiving multi vs. single-species probiotic formulations were similar in our study. In view of the sample size and low baseline rate of NEC in our unit, further trials are warranted to investigate the effects of specific probiotics for prevention of serious neonatal morbidities.
3rd Faculty of Medicine Charles University Prague 100 00 Czech Republic
Institute for the Care of Mother and Child Neonatology Prague 147 00 Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013352
- 003
- CZ-PrNML
- 005
- 20240905133344.0
- 007
- ta
- 008
- 240725e20240522ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.earlhumdev.2024.106054 $2 doi
- 035 __
- $a (PubMed)38795665
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Korček, Peter $u Institute for the Care of Mother and Child, Neonatology, Prague 147 00, Czech Republic; Third Faculty of Medicine, Charles University, Prague 100 00, Czech Republic. Electronic address: peter.korcek@upmd.eu
- 245 10
- $a No differences were observed in the prevention of necrotizing enterocolitis and late-onset sepsis among preterm infants who received either single-species or multi-species probiotics / $c P. Korček, Z. Straňák
- 520 9_
- $a BACKGROUND: Probiotic prophylaxis has been suggested to reduce the incidence of necrotizing enterocolitis (NEC) and late-onset sepsis (LOS) in very preterm newborns. However, choosing the optimal probiotic is difficult due to variations in strain-specific effects and interactions facilitated by the use of combination species. AIMS: To compare clinical outcomes of very preterm infants receiving multi or single-species probiotics. STUDY DESIGN: Retrospective, single-center, cohort study. SUBJECTS: Very preterm infants (<32 weeks' gestation) born between 2019 and 2022 at a tertiary perinatal center received either a multi-species (Lactobacillus rhamnosus 45 %, Lactobacillus casei 15 %, Lactobacillus acidophilus 15 %, Bifidobacterium infantis 15 %, Bifidobacterium bifidum 10 %; n = 228) or a single-species (Bifidobacterium breve BR03 and B632; n = 227) probiotic formulation. MAIN OUTCOME MEASURES: NEC, LOS, and mortality. RESULTS: The overall incidence of NEC and LOS was 3.1 % and 13.8 %, respectively. There were no differences between the multi-species and single-species probiotic groups in the rate of NEC (3.5 % vs 2.6 %; p = 0.787), LOS (15.4 % vs 12.3 %; p = 0.416), mortality (0.9 % vs 1.8 %; p = 0.449), or composite outcome (NEC, LOS and/or death; 16.7 % vs 12.8 %; p = 0.290). CONCLUSION: The clinical outcomes of very preterm newborns receiving multi vs. single-species probiotic formulations were similar in our study. In view of the sample size and low baseline rate of NEC in our unit, further trials are warranted to investigate the effects of specific probiotics for prevention of serious neonatal morbidities.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a probiotika $x terapeutické užití $7 D019936
- 650 12
- $a nekrotizující enterokolitida $x prevence a kontrola $x epidemiologie $7 D020345
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a novorozenec nedonošený $7 D007234
- 650 _2
- $a sepse $x prevence a kontrola $x epidemiologie $7 D018805
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a nemoci nedonošenců $x prevence a kontrola $x epidemiologie $7 D007235
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Straňák, Zbyněk $u Institute for the Care of Mother and Child, Neonatology, Prague 147 00, Czech Republic; Third Faculty of Medicine, Charles University, Prague 100 00, Czech Republic
- 773 0_
- $w MED00001465 $t Early human development $x 1872-6232 $g Roč. 194 (20240522), s. 106054
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38795665 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133338 $b ABA008
- 999 __
- $a ok $b bmc $g 2143270 $s 1225218
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 194 $c - $d 106054 $e 20240522 $i 1872-6232 $m Early human development $n Early Hum Dev $x MED00001465
- LZP __
- $a Pubmed-20240725